Dermatology
Original Paper
Effectiveness of Infliximab in Pityriasis Rubra Pilaris Is Associated with Pro-Inflammatory Cytokine InhibitionAdnot-Desanlis L.a · Antonicelli F.c · Tabary T.b · Bernard P.a, c · Reguiaï Z.aDepartments of aDermatology and bImmunology, Reims University Hospital, and cLaboratory of Dermatology, Reims Champagne-Ardenne University, Reims, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 20, 2012
Accepted: December 18, 2012
Published online: March 19, 2013
Issue release date: May 2013
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 3
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
Background: Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease. Recently, the use of anti-TNF-α in treating resistant forms of PRP has been reported. Objectives: To evaluate the clinical efficacy of infliximab in the treatment of PRP along with the evolution of secretion of some serum cytokines during treatment. Methods: Patients presenting widespread PRP were included consecutively and treated with infliximab. We compared cytokine profiles (notably CXCL-10 and TNF-α) by ELISA in sera from both patients with PRP and controls (healthy/psoriasis) at the time of diagnosis and after clinical remission (PRP). Results: 4 patients were treated with infliximab and achieved complete remission without any recurrence after treatment ending. The serum level of TNF-α and CXCL-10 was increased at the time of inclusion and normalized after treatment. Analysis of the typical component of the T helper cell 1 (Th1) and Th2 cytokine network did not show modification. Conclusion: Infliximab is an effective treatment of PRP. The analysis of the cytokine profile is in agreement with an absence of further recurrence of PRP by an early and unique inflammatory mechanism without significant underlying autoimmunity.
© 2013 S. Karger AG, Basel
Related Articles:
References
- Soeprono FF: Histologic criteria for the diagnosis of pityriasis rubra pilaris. Am J Dermatopathol 1986;8:277-283.
- Griffiths WA: Pityriasis rubra pilaris. Clin Exp Dermatol 1980;5:105-112.
- Griffiths WA, Ozluer S: Pityriasis rubra pilaris. Ann Dermatol Venereol 2001;128:931-934.
- Magro CM, Crowson AN: The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol 1997;24:416-424.
- Niemi KM, Kousa M, Storgards K, Karvonen J: Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens. Dermatologica 1976;152:109-118.
- Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al: Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012;91:163-170.
- Finzi AF, Altomare G, Bergamaschini L, Tucci A: Pityriasis rubra pilaris and retinol-binding protein. Br J Dermatol 1981;104:253-256.
- Ivanova K, Itin P, Haeusermann P: Pityriasis rubra pilaris: treatment with biologics - a new promising therapy? Dermatology 2012;224:120-125.
- Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S: Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol 2008;22:117-118.
- Cox V, Lesesky EB, Garcia BD, O'Grady TC: Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol 2008;59:S113-S114.
- Walling HW, Swick BL: Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol 2009;145:99-101.
- Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A: Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol 2007;143:1597-1599.
- Manoharan S, White S, Gumparthy K: Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006;47:124-129.
- Müller H, Gattringer C, Zelger B, Höpfl R, Eisendle K: Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol 2008;59:S65-S70.
- Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, Gamo-Villegas R, Calzado-Villarreal L, Pinedo-Moraleda F: Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol 2007;87:552-553.
- Liao WC, Mutasim DF: Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141:423-425.
- Wohlrab J, Kreft B: Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 2010;163:655-656.
- O'Kane D, Devereux CE, Walsh MY, Hoey SEH: Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol 2010;35:e155-e156.
- Ruiz Villaverde R, Sánchez Cano D: Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol 2010;20:630-631.
- Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies R-M: Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol 2010;35:792-793.
- Vasher M, Smithberger E, Lien MH, Fenske NA: Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol 2010;9:844-850.
- Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B: Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol 2010;24:881-884.
- Guedes R, Leite L: Therapeutic hotline. Treatment of pityriasis rubra pilaris with etanercept. Dermatol Ther 2011;24:285-286.
- Griffiths WA: Pityriasis rubra pilaris: the problem of its classification. J Am Acad Dermatol 1992;26:140-142.
- Dessinioti C, Vergou T, Moustou E, Katsambas A, Antoniou C: Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol 2011;21:599-600.
- Zhang Y-H, Zhou Y, Ball N, Su M-W, Xu J-H, Zheng Z-Z: Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg 2010;14:185-188.
- Klein A, Szeimies R-M, Landthaler M, Karrer S: Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology 2007;215:72-75.
- Lu R, George SJ, Hsu S: Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J 2006;12:18.
- Jacob SE, Nassiri M, Kerdel FA, Vincek V: Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003;12:309-313.
- Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H: Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010;35:645-649.
- Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009;361:496-509.
- Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-898.
- Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-2587.
Article / Publication Details
Received: August 20, 2012
Accepted: December 18, 2012
Published online: March 19, 2013
Issue release date: May 2013
Number of Print Pages: 6
Number of Figures: 4
Number of Tables: 3
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
